药康生物: 关于作废部分已授予尚未归属的限制性股票的公告

Core Viewpoint - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. has announced the cancellation of certain unvested restricted stocks granted under its 2022 incentive plan due to the departure of three incentive recipients, adjusting the total number of recipients and shares accordingly [1][4][5] Group 1: Decision Process and Disclosure - The company has completed the necessary decision-making procedures and disclosed information regarding the 2022 restricted stock incentive plan [1] - Independent directors provided opinions on the incentive plan proposals, and the supervisory board verified the related matters [1][3] Group 2: Specifics of Stock Cancellation - The cancellation of restricted stocks was due to the departure of three incentive recipients, leading to a reduction in the number of initial recipients from 17 to 14 [4][5] - The total number of restricted stocks granted was adjusted from 962,000 shares to 872,000 shares, resulting in the cancellation of 90,000 shares [5] Group 3: Impact on the Company - The cancellation of these restricted stocks is not expected to have a significant impact on the company's operational situation or the stability of its technical and management teams [5] - The ongoing implementation of the stock incentive plan remains unaffected by this cancellation [5] Group 4: Supervisory Board and Legal Opinions - The supervisory board agrees that the cancellation of unvested restricted stocks complies with relevant laws and regulations, and does not harm shareholder interests [5] - Legal opinions confirm that the cancellation has obtained necessary approvals and aligns with applicable regulations [5]